Lipella Pharmaceuticals Commences Phase 2a Trial For LP-310 In Oral Lichen Planus, Enrolls First Patients
Author: Benzinga Newsdesk | July 29, 2024 05:04am
Lipella's Phase 2a trial is a multi-center, dose-ranging study of LP-310, a proprietary liposomal-tacrolimus oral rinse formulation of the company's lead candidate LP-10 for hemorrhagic cystitis. The trial has enrolled its first patients across multiple research sites nationwide, spanning from Philadelphia to San Francisco, and is actively screening additional subjects with symptomatic Oral Lichen Planus.
Posted In: LIPO